

## Proteomic Infrastructure for Clinical Diagnostics

---

### Clinical Diagnostic Translation & Deployment Overview

BioTAS™ enables structured translation progression of quantitative plasma protein signatures into analytically validated, clinically deployable laboratory-developed tests.

### WHO WE ARE

Proteas Health is a U.S.-based biotechnology company delivering the globally patented BioTAS™ platform – a blood proteomics infrastructure engineered to support progression from signature discovery through CLIA-certified analytical validation to scalable clinical laboratory deployment. The platform integrates decentralized blood collection, controlled plasma stabilization, high-resolution quantitative mass spectrometry and longitudinal computational modeling to generate reproducible, development-grade protein measurements from minimal sample volumes.

### HOW WE SUPPORT DIAGNOSTIC DEVELOPMENT

#### Quantitative Signature Discovery

Identification of plasma protein patterns supporting early detection, risk stratification, and longitudinal disease monitoring.

#### Analytical Validation & Assay Design

Development of targeted quantitative assays with defined performance characteristics, including reproducibility, linearity, and inter-instrument consistency.

#### CLIA-Certified Laboratory Deployment

Validation and deployment within a CLIA-certified environment, with standardized, regulatory-grade workflows enabling transfer to external clinical laboratories.

#### Commercial Transition & Licensing

Progression from validated assay to distributed laboratory implementation and licensing frameworks.

### PLATFORM CAPABILITIES

#### Affinity-Independent Quantitative Measurement

Mass spectrometry-based plasma proteomics beyond predefined antibody or panel constraints.

#### Controlled Pre-Analytical Handling

Globally patented (PCT/US2021/063407) plasma isolation and stabilization supporting decentralized collection with minimized variability.

#### Reproducible Clinical-Scale Measurement

Automated, multiplexed quantitative workflows designed for regulated laboratory environments.

#### Systems-Level Longitudinal Pattern Modeling

Computational analysis of protein signatures supporting stratification, monitoring, and clinical decision frameworks.

### **Inter-Laboratory Transfer Compatibility**

Standardized analytical workflows enabling scalable implementation across clinical laboratory networks.

### **CLINICAL APPLICATION SCOPE**

BioTAS™ supports development and validation of quantitative blood-based assays enabling earlier diagnosis, risk stratification, longitudinal disease monitoring, and patient-specific management across diverse clinical domains, including:

- Oncology
- Cardiometabolic disease
- Infectious disease
- Autoimmune disorders
- Neurodegenerative disease

### **SELECTED PROGRAM EXPERIENCE**

- **Cardiovascular Risk Stratification**  
Identified and validated quantitative plasma protein signatures supporting coronary artery disease risk assessment.
- **Hematologic Oncology Risk Stratification – Smoldering Multiple Myeloma**  
Identified plasma signatures predictive of progression to active multiple myeloma.
- **Longitudinal Disease Monitoring – Alzheimer’s Disease**  
Plasma and CSF proteomic profiling for the development of longitudinal monitoring assays.

### **TRANSLATIONAL CONTINUITY**

BioTAS™ preserves analytical consistency from discovery-stage proteomic profiling through CLIA-certified validation and laboratory deployment. The infrastructure supports progression from exploratory signature identification to standardized laboratory-developed tests without reconfiguring core analytical workflows.

### **COLLABORATION**

We partner with diagnostic developers to translate quantitative proteomic signatures into analytically validated, CLIA-aligned clinical laboratory assays.